



VOLUME 10 SUPPLEMENT 1 JUNE 2006 ISSN 1201-9712



# International Journal of Infectious Diseases

12TH ICID ABSTRACTS  
Lisbon Portugal • June 15–18, 2006



OFFICIAL PUBLICATION OF THE INTERNATIONAL  
SOCIETY FOR INFECTIOUS DISEASES





# International Journal of Infectious Diseases

OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES

## **Editor-in-Chief**

Jonathan Cohen  
Dean, Brighton & Sussex Medical School  
IJID Editorial Office  
University of Sussex  
Brighton BN1 9PX, United Kingdom

## **Journal Administrator**

Jackie Parker  
IJID Editorial Office  
Tel: 144 1273 877578 Fax: 144 1273 877576  
ijid@bsms.ac.uk

## **Corresponding Editors**

**Prof. Salim S. Abdool Karim**  
Durban, South Africa  
karims1@ukzn.ac.za

**Dr. Timothy Barkham**  
Singapore  
timothy\_barkham@ttsh.com.sg

**Dr. J. Peter Donnelly**  
Nijmegen, The Netherlands  
p.donnelly@usa.net

**Prof. Michael Ellis**  
Al Ain, UAE  
michael.ellis@uaeu.ac.ae

**Prof. Andy I.M. Hoepelman**  
Utrecht, The Netherlands  
i.m.hoepelman@umcutrecht.nl

**Dr. Sohar Oman**  
Bethesda, USA  
rsmego@hsc.wvu.edu

**Dr. Richard A. Oberhelman**  
New Orleans, USA  
oberhel@tulane.edu

**Dr. Michael Whitby**  
Brisbane, Australia  
whitbym@health.qld.gov.au

**Dr. Jane Zuckerman**  
London, UK  
j.zuckerman@medsch.ucl.ac.uk

## **International Society for Infectious Diseases**

### **Executive Committee**

Francisco Antunes, Portugal  
Keryn Christiansen, Australia, President  
Raul Isturiz, Venezuela  
Dennis L. Kasper, USA, Past President  
Keith Klugman, USA

Carl Erik Nord, Sweden, Treasurer  
Heikki Peltola, Finland  
Didier Raoult, France  
Jingoro Shimada, Japan, Secretary  
Richard Wenzel, USA, President-elect

### **Publications Committee**

Jean-Paul Butzler  
Jonathan Cohen  
Alasdair Geddes  
Dennis Kasper, Chair  
Richard Wenzel

### **Council**

Guillermo Acuña, Chile  
Awa Kane Aidara, Switzerland  
Mohammed Benbachir, Morocco  
S.M. Bhatt, Kenya  
N.C. Bodoaik, Jamaica  
Rosa Bologna, Argentina  
Mary Jane Cardoso, Malaysia  
Kang Won Choe, Korea  
Ron Dagan, Israel  
Adriano G. Duse, South Africa  
Luiza-Helena Falleiros-Carvalho,  
Brazil  
Roger Finch, United Kingdom  
Wang Fu, China  
Le Dang Ha, Vietnam  
Waleria Hryniewicz, Poland  
Salah A. Ibrahim, Sudan  
Moses Kanya, Uganda  
Meinoif Karthaus, Germany  
Gustavo Kourí, Cuba  
Vladimír Kráméry, Slovak Republic  
N. Kumarasamy, India

Christopher Lee, Malaysia  
Philippe Lepage, Belgium  
Daniel Lew, Switzerland  
Donald Low, Canada  
Chewe Luo, Zambia  
Ziad Memish, Saudi Arabia  
Patricia Munoz, Spain  
Alaine Nyaruhirira, Belgium  
Carla Odio, Costa Rica  
Nobuhiko Okabe, Japan  
Andrew Onderdonk, USA  
Franco Paradisi, Italy  
Mahbubur Rahman, Bangladesh  
Jose Ignacio Santos, Mexico  
Atef M. Shibl, Saudi Arabia  
Zuhayr Tabbarah, Lebanon  
Jaime Torres, Venezuela  
Thelma Tupasi-Ramos, Philippines  
Asda Vibhagool, Thailand  
Maria Virginia Villegas, Colombia  
Richard J. Whitley, USA  
Sin Yew Wong, Singapore

### **Editorial Advisory Board**

Awa Aidara-Kane, Senegal  
Keryn Christiansen, Australia  
Eduardo Gotuzzo, Peru  
King K. Holmes, USA  
Raúl Isturiz, Venezuela  
T. Jacob John, India  
Davy Koech, Kenya  
Shigeru Kohno, Japan  
Keith Klugman, USA  
Vladimír Kráméry, Slovak Republic  
Philippe Lepage, Belgium  
Andrew Lever, UK  
Andrew Onderdonk, USA  
Samuel Ponce de Leon, Mexico  
Didier Raoult, France  
Rino Rappuoli, Italy  
Jae-Hoon Song, Republic of Korea  
Tania Sorrell, Australia  
Thelma Tupasi-Ramos, Philippines

Officers of the ISID may be reached  
at the Society's headquarters by Fax:  
+1 617-731-1541

not include *Proteus*, *Providencia*, and *Pseudomonas* spp. Plasma and urinary levels are modest. Efficacy data are largely for community infections, with modest numbers of bacteraemias. More T than C pts died, and more experienced septic shock, but the imbalances were not statistically significant. GI AEs were common (cSSSI >cIAI>C), but usually mild or moderate; nonetheless, some pts do not tolerate T. Methods to improve GI tolerability are not identified. Increased PT/PTT and bilirubin/ jaundice occur, the latter in predisposed cIAI pts. Increased blood urea and abnormal wound healing likely reflect an anti-anabolic effect.

**Conclusion:** The benefit-risk ratio is favorable in cSSSI and cIAI. Candidate pts include those with polymicrobial surgical wound infection, cSSSI complicating diabetes mellitus, cIAI such as diverticulitis or biliary infection, and allergy to/intolerance of other therapies. More data are needed on the role of T in therapy of nosocomial infection, bacteraemia, and infection caused by *Acinetobacter* spp. and ESBL-producing organisms.

### 29.015 Antiviral Effects of Novel Phenoxazines, Phx-1 and Phx-2 on Poliovirus and Porcine Parvovirus

A. Tomoda<sup>1</sup>, A. Iwata<sup>2</sup>, T. Yamaguchi<sup>2</sup>. <sup>1</sup>Department of Biochemistry, Tokyo Medical University, Tokyo, Japan; <sup>2</sup>Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo, Japan

**Background:** We found that novel phenoxazines such as 2-amino-4, 4a-dihydro-4a, 7-dimethyl-3H-phenoxazine-3-one (Phx-1) and 3-amino-1, 4a-dihydro-4a, 8-dimethyl-2H-phenoxazine-2-one (Phx-2) exert antimicrobial, anticancer and immunosuppressive effects. It may be interesting to study preventive effects of these phenoxazines on viruses.

**Methods:** Phx-1 and Phx-2 were obtained by the reaction of 2-amino-5-methylphenol or 2-amino-4-methylphenol with bovine hemoglobin. Antiviral effects of Phx-1 and Phx-2 on poliovirus and porcine virus were examined after treatment of Vero cells or ESK cells with Phx-1 and Phx-2 for 1 hour at 37°C. Antiviral effects of these phenoxazines were examined for other viruses such as simian virus 40, herpes simplex virus-1, Sindbis virus and vesicular stomatitis virus.

**Results:** Phx-1 and Phx-2 suppressed the proliferation of poliovirus in Vero cells and that of porcine parvovirus in ESK cells at concentrations between 0.25 µg/ml and 2 µg/ml, when the cells were treated with these phenoxazines for 1 h and then inoculated with these viruses. The proliferation of other viruses in the host cells was not affected by these phenoxazines.

**Conclusion:** Present result may suggest that Phx-1 and Phx-2 may be useful to prevent the proliferation of poliovirus and porcine parvovirus infection.

### 29.016 Inhibition by Thyme Oils of Growth, Aflatoxin Production and Ultrastructural Alterations of *Aspergillus parasiticus*

I. Rasooli, H. Amiri Vahid. Shahed University, Tehran, Iran

**Background:** Some *Aspergillus* species are responsible for many cases of food and feed contamination. Aflatoxin producing fungi grow rapidly on a variety of natural substrates and consumption of contaminated food feedstuffs can pose serious health hazards to human and animals. The use of natural antimicrobial compounds is important not only in the preservation of food but also in the control of human and plant diseases of microbial origin.

**Methods:** The antifungal effects of essential oils from *Thymus eriocalyx* and *Thymus x-parlock* were studied with special reference to the inhibition of *Aspergillus parasiticus* growth and aflatoxin production. Minimal inhibitory (MIC) and minimal fungicidal (MFC) concentrations of the oils were determined. The oils analyzed by GC and GC/MS for their chemical constituents. Ultrastructural alterations of the fungus were studied under Transmission Electron Microscope.

**Results:** The oils from the above plants were found to be strongly antimicrobial and inhibitory to aflatoxin production. Static and lethal effects of the above oils against *A. parasiticus* were at 250 and 500-1000ppm of the oils respectively. Aflatoxin production was inhibited at 250ppm of both oils with that of *T. eriocalyx* being stronger inhibitor. The oils analyzed by GC and GC/MS lead to identification of 18 and 19 components in *Thymus eriocalyx* and *Thymus x-parlock* oils respectively. The profile of the oil components from *Thymus eriocalyx* was similar to that of *Thymus x-parlock* in almost all the compounds but at different concentrations. The major components of *Thymus eriocalyx* and *Thymus x-parlock* oils were Thymol

(64.3, 30.7%), beta-phellandrene (13.2, 39.4%) and Cis Sabinene hydroxide (8.4, 9.7%) respectively. Transmission electron microscopy (TEM) of *A. parasiticus* exposed to MIC level (250 ppm) of the oils showed irreversible damage to cell wall, cell membrane and cellular organelles.

**Conclusion:** Substitution of currently used antifungal and aflatoxin inhibiting chemicals by natural compounds such as thyme is recommended.

### 29.017 Search for Antimicrobial Peptides Among Natural Toxins and Venoms

P. Gopalakrishnakone. Venom and Toxin Research Programme, Department of Anatomy, Yong Loo Lin School of Medicine, Singapore

**Background:** *Burkholderia pseudomallei* are the causative agent of melioidosis. It is intrinsically resistant to many antibiotics. Consequently, there is an urgent need to search for alternatives to synthetic antibiotics.

**Methods:** A large library of natural toxins and venoms from snakes, scorpions, spiders and purified PLA2s including ammodytoxin, crotoxin A, crotoxin B, daboiatoxin, taipoxin, mulgatoxin, melittin,  $\alpha$ -bungarotoxin and Mojave toxin were screened for their antimicrobial activity against a wide variety of organisms by disc-diffusion method.

**Results:** The crotoxin B (CB) showed broad spectrum of activity against *S. aureus*, *P. aeruginosa*, *E. aerogenes*, *E. coli* and *B. pseudomallei*. However the CB and daboiatoxin exerted strong antimicrobial activity against *S. aureus* and *B. pseudomallei*. The enzymes were further studied their MIC by MH broth dilution assay at 0.5-0.0315 µM. Enzymes, CB (MICs 0.0125 µM) and daboiatoxin (MICs 0.25 µM) showed strong bacterial inhibition at the lowest dilutions. SEM showed membrane pore formation. Hemolytic property was assayed using human erythrocytes; the enzymes did not show any toxic effect compared to control.

**Conclusion:** This antibacterial profile of snake venom PLA2s reported may be useful agents against drug resistant microorganisms of *B. pseudomallei*.

Pathogenesis caused by *B. pseudomallei* was also studied by infection with human macrophages as well as in mice and guinea pig models after intra peritoneal injections. Also postmortem specimens from infected pigs were studied by Light microscopy, TEM as well as SEM. A complete evolution of the pathogenesis of the organism from entering the macrophage to abscess formation in animal models will be presented using all the microscopic methods.

### 29.018 Adverse Events During Pegylated Interferon/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C

C. Evtimovska, L.J. Ivanovski, M. Gaseva, V. Grunevska, M. Dimzova, B. Tosevski. Clinic for Infectious Disease, Skopje, Former Yugoslav Republic of Macedonia

**Background:** To evaluate the effects of adverse events on the course of therapy with pegylated interferon/ribavirin in patients with CHC.

**Material and Methods:** 89 patients with CHC are treated with pegylated interferon/ribavirin at the Clinic. 45/89 with CHC (19 pts with C1 and 26 pts with C3), were analyzed. Seventy subjective and 3 objective adverse events were taken into account. The methods used were questionnaire and standard laboratory investigations.

**Results:** 63 adverse events were observed in more than 10% of the patients, and 10/63 in more than 50%. More than 50% of the patients with C1 infection experienced 18 adverse events, and only 2 were present in less than 10% of the patients. Nine adverse events occurred in more than 50% of the patients with C3 infection, and less than 10% experienced only 6 adverse events. Discontinuity/dose modification was done in 7 patients (15, 6%); in two because of severe neutropenia, in two because of anemia, in one patient due to neutropenia and thrombocytopenia, in one patient as a result of thrombocytopenia, and in one because of prominent subjective reactions. From total 89 patients with ongoing combination therapy pegylated interferon/ribavirin, the therapy was stopped in 12 (13, 5%); in 5 (5, 6%) as a result of serious adverse events.

**Conclusion:** adverse events are present in large number and in significant proportion of patients treated with pegylated interferon/ribavirin. The length of therapy, according the HCV genotype, has some influence on the percentage of the reported adverse events, as well as the number of patients in which they appear. It should be noticed that all of the reported adverse events disappeared one month after end of treatment.